Antigenesis Biologics specializes in antibody discovery and antigen design for therapeutic development in animal companions. The company leverages expertise in computational biology and structural immunology to address complex challenges in biologics advancement. They partner with innovators to translate biotech concepts into viable, next-generation veterinary solutions.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional methods of antigen design for antibody discovery, diagnostics, and vaccine development often lead to program failures due to suboptimal antigen quality. These failures can result in ineffective medical solutions and increased development costs.
Solution
The startup focuses on antigen engineering, employing computational structural biology to create precise antigen molecules. This approach aims to improve the quality of antigens used in therapeutic antibody discovery, diagnostics, and vaccine development. By focusing on high-quality antigen design, the startup seeks to reduce the risk of program failure and improve the effectiveness of medical solutions.
Target Audience
The primary customers are researchers and companies involved in therapeutic antibody discovery, diagnostics development, and vaccine development.
Features
- Computational structural biology for precise antigen design
- Antigen engineering for therapeutic antibody discovery
- Antigen engineering for diagnostics
- Antigen engineering for vaccine development